| New England Podiatry Associates, P.c. | |
|
1244 Boylston St, Suite 101, Chestnut Hill, MA 02467-2116 | |
| (617) 232-1752 | |
| Not Available |
| Full Name | New England Podiatry Associates, P.c. |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot Surgery |
| Location | 1244 Boylston St, Chestnut Hill, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972648467 | NPI | - | NPPES |
| 9740333 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | 1948 (Massachusetts) | Primary |
| Provider Name | Alan H Green |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1689698441 PECOS PAC ID: 2062449671 Enrollment ID: I20050725001012 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Provider Name | Michael Ira Hass |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1437173291 PECOS PAC ID: 2961429329 Enrollment ID: I20051026000141 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Provider Name | Stephen P Tubridy |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1104840974 PECOS PAC ID: 7911916705 Enrollment ID: I20060405000628 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Provider Name | Ronald B Etskovitz |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1578587085 PECOS PAC ID: 6709895535 Enrollment ID: I20060406000191 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Provider Name | Raymond Salvatore Murano |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1114309325 PECOS PAC ID: 6305198128 Enrollment ID: I20181005001533 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Provider Name | Zachary Caleb Sax |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1669904140 PECOS PAC ID: 8224376520 Enrollment ID: I20200803002124 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Provider Name | Catherine Jacobs |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1174050637 PECOS PAC ID: 8921427626 Enrollment ID: I20200930000252 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| New England Podiatry Associates, P.c. 1244 Boylston Street, Suite 101, Chestnut Hill, MA 02467-2115 Ph: (617) 232-1752 | New England Podiatry Associates, P.c. 1244 Boylston St, Suite 101, Chestnut Hill, MA 02467-2116 Ph: (617) 232-1752 |
News Archive
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.
Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.
Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.
› Verified 8 days ago
Dr. Stephen Patrick Tubridy, D.P.M. Podiatrist Medicare: Medicare Enrolled Practice Location: 1244 Boylston St, Suite 101, Chestnut Hill, MA 02467 Phone: 617-232-1752 Fax: 617-566-1919 | |
Dr. Helen Cho, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 291 Independence Dr, Chestnut Hill, MA 02467 Phone: 617-541-6675 | |
Dr. Michael Ira Hass, D.P.M. Podiatrist Medicare: Medicare Enrolled Practice Location: 1244 Boylston St, Suite 101, Chestnut Hill, MA 02467 Phone: 617-232-1752 Fax: 617-566-3919 | |
Jems Foot Care Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 1244 Boylston St Fl 101, Chestnut Hill, MA 02467 Phone: 617-232-1752 Fax: 617-566-3919 | |
Dr. Ronald Brian Etskovitz, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1244 Boylston St, Suite 101, Chestnut Hill, MA 02467 Phone: 617-232-1752 Fax: 617-566-3919 | |
Dr. Lindsay Jessica Johnson, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 291 Independence Dr, Podiatry Dept., Chestnut Hill, MA 02467 Phone: 617-541-6611 Fax: 617-541-7550 | |
Dr. Zachary C Sax, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1244 Boylston Street, Suite 101, Chestnut Hill, MA 02467 Phone: 617-232-1752 Fax: 617-566-3919 |